Kundu Manjari, Greer Yoshimi E, Lobanov Alexei, Ridnour Lisa, Donahue Renee N, Ng Yeap, Ratnayake Shashi, White Karley, Voeller Donna, Weltz Sarah, Chen Qingrong, Lockett Stephen J, Cam Maggie, Meerzaman Daoud, Wink David A, Weigert Roberto, Lipkowitz Stanley
Women's Malignancies Branch, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
Center for Cancer Research Collaborative Bioinformatics Resource (CCBR), NCI, NIH, Bethesda, MD, USA.
Cancer Lett. 2025 Jun 28;620:217692. doi: 10.1016/j.canlet.2025.217692. Epub 2025 Apr 3.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential cancer therapeutic that induces apoptosis in cancer cells while sparing the non-malignant cells in preclinical models. However, its efficacy in clinical trials has been limited, suggesting unknown mechanisms modulating TRAIL activity in patients. We hypothesized that TRAIL treatment elicits transcriptional changes in triple negative breast cancer (TNBC) cells that alter the immune milieu. RNAseq analysis of MDA-MB-231 cells along with validation in additional cell lines demonstrated that TRAIL induced cytokines such as CXCLs 1, 2, 3, 8,11 and IL-6, which are known to modify neutrophil function. Mechanistically, TRAIL dependent induction of the cytokines was predominantly mediated by death receptor 5, caspase-8 and the non-canonical NFKB2 pathway. These cytokines produced by TRAIL-treated TNBC cells enhanced chemotaxis of normal human donor isolated neutrophils. Using TNBC xenograft models, TRAIL induced activation of NFkB2 pathway, cytokine production and increased neutrophil recruitment into the tumors. Moreover, preincubation of neutrophils in supernatants from TRAIL-treated TNBC cells significantly impaired neutrophil function as measured by reduced respiratory burst and cytotoxic effect against TNBC cells. Transcriptomic analysis of neutrophils incubated with either TRAIL alone or supernatant of TRAIL-treated TNBC cells revealed increased expression of inflammatory cytokines, immune modulatory genes, immune checkpoint genes, and genes implicated in delayed neutrophil apoptosis. Functional studies showed that these neutrophils suppress T cell proliferation and augment Treg suppressive phenotype. Collectively, our study demonstrates a novel role of TRAIL-induced NFKB2-dependent cytokine production that promotes neutrophil chemotaxis and neutrophil-mediated immune suppression.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)是一种潜在的癌症治疗药物,在临床前模型中,它可诱导癌细胞凋亡,同时使非恶性细胞免受影响。然而,其在临床试验中的疗效有限,这表明在患者中调节TRAIL活性的机制尚不清楚。我们推测,TRAIL治疗会引发三阴性乳腺癌(TNBC)细胞的转录变化,从而改变免疫微环境。对MDA-MB-231细胞进行RNA测序分析,并在其他细胞系中进行验证,结果表明TRAIL可诱导细胞因子如CXCLs 1、2、3、8、11和IL-6的产生,已知这些细胞因子可改变中性粒细胞功能。从机制上讲,TRAIL依赖性细胞因子的诱导主要由死亡受体5、半胱天冬酶-8和非经典NFKB2途径介导。TRAIL处理的TNBC细胞产生的这些细胞因子增强了从正常人类供体分离出的中性粒细胞的趋化性。使用TNBC异种移植模型,TRAIL诱导NFkB2途径的激活、细胞因子的产生,并增加肿瘤中中性粒细胞的募集。此外,用TRAIL处理的TNBC细胞的上清液对中性粒细胞进行预孵育,通过降低呼吸爆发和对TNBC细胞的细胞毒性作用来衡量,显著损害了中性粒细胞功能。对单独用TRAIL或TRAIL处理的TNBC细胞上清液孵育的中性粒细胞进行转录组分析,发现炎性细胞因子、免疫调节基因、免疫检查点基因以及与中性粒细胞凋亡延迟相关的基因表达增加。功能研究表明,这些中性粒细胞抑制T细胞增殖并增强调节性T细胞的抑制表型。总体而言,我们的研究证明了TRAIL诱导的NFKB2依赖性细胞因子产生具有促进中性粒细胞趋化和中性粒细胞介导的免疫抑制的新作用。